+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Selective Serotonin Reuptake Inhibitor"

From
From
Depression Drugs Market - Global Strategic Business Report - Product Thumbnail Image

Depression Drugs Market - Global Strategic Business Report

  • Report
  • May 2026
  • 380 Pages
  • Global
From
From
From
From
Antidepressants - Global Strategic Business Report - Product Thumbnail Image

Antidepressants - Global Strategic Business Report

  • Report
  • May 2026
  • 174 Pages
  • Global
From
From
From
From
From
Treatment Resistant Depression Drug Pipeline Analysis Report 2025 - Product Thumbnail Image

Treatment Resistant Depression Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • June 2025
  • 200 Pages
  • Global
From
From
Postpartum Depression Epidemiology Forecast 2025-2034 - Product Thumbnail Image

Postpartum Depression Epidemiology Forecast 2025-2034

  • Report
  • June 2025
  • 150 Pages
  • Global
From
From
From
From
From
From
Loading Indicator

Selective Serotonin Reuptake Inhibitors (SSRIs) are a class of drugs used to treat mental disorders such as depression, anxiety, and obsessive-compulsive disorder. SSRIs work by increasing the amount of serotonin, a neurotransmitter, in the brain. This helps to improve mood and reduce symptoms of mental illness. SSRIs are generally considered to be safer and more effective than other types of antidepressants, and they are often prescribed as a first-line treatment for mental disorders. The SSRI market is highly competitive, with many pharmaceutical companies offering different brands of SSRIs. Some of the major players in the market include Pfizer, GlaxoSmithKline, Eli Lilly, and AstraZeneca. These companies have developed a wide range of SSRIs, including Prozac, Zoloft, Paxil, and Lexapro. Other companies, such as Mylan and Teva, also offer generic versions of SSRIs. Show Less Read more